home / stock / okyo / okyo news

OKYO News and Press, OKYO Pharma Limited From 03/20/24

Stock Information
Company Name: OKYO Pharma Limited
Stock Symbol: OKYO
Market: NASDAQ
Website: okyopharma.com
Menu
OKYO OKYO Quote OKYO Short OKYO News OKYO Articles OKYO Message Board
Get OKYO Alerts

News, Short Squeeze, Breakout and More Instantly...
OKYO - OKYO Pharma to Release New and Comprehensive Data from Phase 2 Dry Eye Disease Trial and Host Key Opinion Leader Event

LONDON and NEW YORK, March 20, 2024 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative ocular therapies for the treatment of inflammatory dry eye disease (DED), a multi-billion-dollar market, and anterior ocular segment disease...
OKYO - VUZI, TCBP and MANU among pre-market losers

2024-02-12 08:27:22 ET More on Pre-market losers & stocks. Manchester United: Public Market Discount Manchester United: A Historic Giant Facing Valuation Challenges And Why It's Time To Sell Knives Are Out For Vuzix Corporation Manchester United appoints ...

OKYO - OKYO Pharma gains on receiving FDA nod of IND for OK-101 in neuropathic corneal pain

2024-02-09 09:01:46 ET More on OKYO Pharma Seeking Alpha’s Quant Rating on OKYO Pharma Historical earnings data for OKYO Pharma Financial information for OKYO Pharma Read the full article on Seeking Alpha For further details see: OKYO Pharm...

OKYO - OKYO Pharma Receives FDA Approval of IND for OK-101 in Neuropathic Corneal Pain

OK-101 is the first IND clearance granted by FDA for a drug to begin clinical studies specifically to treat patients suffering with neuropathic corneal pain (NCP), a major unmet medical need The initial trial of OK-101 to treat NCP is designed as a randomized, placebo-controlled, double-m...
OKYO - OKYO Pharma Announces Distinguished Ophthalmologists with Expertise in the Medical and Surgical Treatment of Ocular Surface Diseases Join its Scientific Advisory Board

LONDON and NEW YORK, Jan. 31, 2024 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative therapies for the treatment of inflammatory dry eye disease (DED), a multi-billion-dollar market, and for neuropathic corneal pain (NCP), a s...

OKYO - CYCC, SGD and ACON among pre-market losers

2024-01-09 08:21:38 ET More on Pre-market losers $ stocks. Cyclacel Pharmaceuticals, Inc. (CYCC) Q3 2023 Earnings Call Transcript Cyclacel Pharmaceuticals announces registered direct and private placement offering Financial information for Aclarion, Inc. Seek...

OKYO - OKYO Pharma Announces OK-101 Successfully Achieved Statistical Significance for Both Sign and Symptom Endpoints in its First-in-Human Phase 2 Trial of OK-101 in Patients with Dry Eye Disease

Statistically significant drug effects were observed in FDA-recognized efficacy endpoints as early as the 15-day first visit after dosing Statistically significant improvement was observed in both a “sign” (total conjunctival staining) and two “symptoms” (burni...
OKYO - OKYO Pharma to Present at the Biotech Showcase Conference in San Francisco, January 8-10, 2024

LONDON and NEW YORK, Jan. 05, 2024 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative therapies for the treatment of inflammatory dry eye disease (DED), a multi-billion-dollar market, and for neuropathic corneal pain, a severe ...

OKYO - OKYO Pharma Announces Last Patient Enrolled in OK-101 Phase 2 Clinical Trial to Treat Dry Eye Disease Has Completed Final Protocol Visit

LONDON and NEW YORK, Dec. 04, 2023 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative therapies for the treatment of inflammatory dry eye disease (DED), a multi-billion-dollar market, and for neuropathic corneal pain, a severe ...

OKYO - OKYO Pharma announces $5.84M cash raise and payables reduction

2023-10-31 13:18:43 ET More on OKYO Pharma OKYO shares retreat 12% after rallying ahead of Phase 2 study update OKYO Pharma announces capital raise of $3.95M without any underwriter or agent Financial information for OKYO Pharma For further details see: O...
Previous 10 Next 10